Jörn Aldag resigns as CEO of Evotec AG

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ:
EVTC) announced today that Jörn Aldag will resign from his position
as President & Chief Executive Officer of Evotec. The resignation
will be effective as of December 31, 2008. Dr Mario Polywka, Chief
Operating Officer, and Dr Klaus Maleck, Chief Financial Officer, will
jointly lead the Company until a permanent successor is announced.

Dr Flemming Ornskov, Chairman of the Supervisory Board of Evotec,
said: "During his eleven-year tenure at Evotec Jörn Aldag played a
pivotal role in the transformation of Evotec from a technology
provider to an integrated, CNS-focused biopharmaceutical company.
Today the Company has a very strong financial position and a deep
preclinical and clinical pipeline of CNS drug candidates that provide
a strong basis for future success. On behalf of the Evotec
Supervisory Board, I would like to thank Jörn Aldag for his effective
and very successful leadership of the Company and we wish him ongoing
success for his future endeavors."

Contact:
Anne Hennecke, SVP, Investor Relations & Corporate Communications,
Evotec AG, Phone: +49-40-56081-286, anne.hennecke@evotec.com

--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480; ISIN:
DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All
Share;
Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Prime
Standard in Frankfurter Wertpapierbörse,
Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München,

Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover;
Copyright © Hugin AS 2008. All rights reserved.